Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054378 | 1.00 | NPSR1 (0.47) | NPSR1ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL29679379 | 0.81 | ALDH1A1 (0.51) | NPSR1ALDH1A1KDM4EL3MBTL1PKM | |
| SCHEMBL240027 | 0.81 | ALDH1A1 (0.51) | NPSR1ALDH1A1KDM4EL3MBTL1PKM | |
| SCHEMBL15093907 | 0.81 | NPSR1 (0.50) | NPSR1ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL15834206 | 0.81 | CNR1 (0.41) | ALDH1A1KMT2AGAALMNA | |
| SCHEMBL20098657 | 0.81 | TARBP2 (0.49) | NPSR1ALDH1A1KDM4EL3MBTL1RAB9A | |
| SCHEMBL31284830 | 0.81 | TARBP2 (0.49) | NPSR1ALDH1A1KDM4EL3MBTL1RAB9A | |
| SCHEMBL25198769 | 0.80 | S1PR4 (0.49) | NPSR1ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL1428189 | 0.80 | NPSR1 (0.48) | NPSR1ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL20745210 | 0.80 | NPSR1 (0.48) | NPSR1ALDH1A1KDM4ESMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709714-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-4658657-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Mirati Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4646271-A1 | SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES | Mirati Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2931734-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014099578-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099578-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2098517-B1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | MSD KK (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-8367708-B2 | Phenyl-isoxazol-3-ol derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2098517-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | NPSR1 2211/4885ALDH1A1 198/4885KDM4E 502/4885 |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | NPSR1 339/4885ALDH1A1 230/4885KDM4E 4053/4885 |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | PIK3CA, PIK3R4, PIK3R1 | NPSR1 1843/4885ALDH1A1 2781/4885KDM4E 1342/4885 |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | GPR119, FFAR3, FFAR2 | NPSR1 248/4885ALDH1A1 2105/4885KDM4E 2580/4885 |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | NPSR1 4347/4885ALDH1A1 4125/4885KDM4E 4320/4885 |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | GCK, GCKR, HK2 | NPSR1 4589/4885ALDH1A1 1590/4885KDM4E 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.